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Abstract
Background: Autologous chondrocyte transplantation is a promising technique for treatment of cartilage defects.
Three dimensional chondrocyte cultures on a scaffold are widely used to retain the chondrogenic phenotype.
Using a biodegradable gelatin scaffold is one option for the cell delivery system, but molecular and histological
studies of the method have not yet been done.
Methods: We evaluated the chondrogenic property of the primary human chondrocyte on a gelatin scaffold as
compared to a collagen scaffold over a period of 21 days. We examined the production of glycosaminoglycan by
quantitative and histological analysis. Gene expression of cartilage-associated molecules was assessed by
quantitative RT-PCR.
Results: The gelatin scaffold showed the ability to promote chondrocyte expansion, chondrogenic phenotype
retention at molecular and mRNA levels.
Conclusions: This scaffold is thus suitable for use as an in vitro model for chondrocyte 3D culture.
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Introduction
Articular chondrocytes have limited ability to self-repair,
and usually dedifferentiate to fibroblasts when grown in
a monolayer culture. A three–dimensional (3D) culture
system can be used to retain the chondrogenic pheno-
type. Matrix induced autologous chondrocyte implant-
ation (MACI), a third generation ACI technique, was
introduced in 1998 and developed as a treatment for
chondral and subchondral defects of joint surfaces [1,2].
During the 5 years following its introduction, the tech-
nique underwent clinical improvements and proved
suitable for treatment of cartilage defects [1]. A bio-
degradable scaffold is needed as a vehicle to deliver the
precultured chondrocytes to the cartilage defects. The
biomaterial scaffolds provide a suitable environment for
chondrocytes to maintain their chondrogenic phenotype.
Various types of natural substance scaffolds include
fibrin, agarose [3], alginate [4], collagen [5,6], chitosan
[7] and hyaluronan [8]. In addition supplementary meth-
ods include conditional use of 3D culture, hormones [9],
growth factors [10], variation of oxygen tension [11],
mechanical stimulation [12] and retrovirally transduced
SOX9 genes in the chondrocytes [13]. The ideal scaffold
should promote the chondrocytes to produce extracellu-
lar matrix, which constitutes the regenerated cartilage.
It has previously been shown that a gelatin-based scaf-
fold (Spongostan™, Johnson & Johnson, Norderstedt,
Germany) may be used as a 3D chondrocyte matrix [14].
Most studies have reported the total extracellular matrix
production rather than glycosaminoglycan concentra-
tion. In this study we determined whether human articu-
lar chondrocytes embedded in a gelatin based scaffold
could retain the chondrogenic properties required for
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chondrocyte transplantation, and compared this to colla-
gen based scaffolds. We then performed quantitative
biochemical and histomorphological analysis over a
period of 21 days.
Materials and methods
Cell culture and reagents
Human chondrocytes from non-osteoarthritis joints
were harvested from notchpalsty operation from articu-
lar knee cartilage of 18–45 years old patients and chon-
drocytes were isolated and purified by standard protocol.
All patients gave consent and all procedures of this
study were approved by the Ethical Committee of
Chiang Mai University (approval no. 070CT111016).
The gelatin scaffold was obtained from Johnson &
Johnson (Germany). The collagen scaffold was pur-
chased from BD Bioscience.
All materials and reagents used in this study were pur-
chased from Sigma (Sigma –Aldrich USA) unless stated
otherwise.
Cell seeding and culture of scaffold
The primary human chondrocytes were grown and
expanded as a monolayer in 10% (v/v) FCS DMEM
(Gibco, Germany) containing 10 U/ml penicillin and 100
μg/ml streptomycin up to passage 4 (P4) for use in these
experiments. Scaffold cultures were performed by dir-
ectly seeding the chondrocytes (5×105 cells suspension
in 30 μl culture medium), onto the scaffold and leaved
the chondrocytes suspension adsorbed and embedded in
scaffold for 4 hrs. After that added chondrogenic media
compose of DMEM supplemented with 10% FBS, 1X
ITS +1, 25 μg/ml ascorbic acid 2-phosphate, 10-7 M
dexamethasone, 10 ng/ml TGF-β and 100 ng/ml IGF-1
and allowed to adhere in a humidified incubator (37°C,
5% CO2) for 24 hrs. The chondrocytes embedded in the
scaffolds were transferred to new culture wells. The
numbers of non-adhering cells were measured by trypsi-
nization of the culture well adhering cells and counted
by a hemacytometer.
Extracellular matrix (ECM) biomolecules assay
s-GAG assay
The sulfated glycosaminoglycan (s-GAG) was deter-
mined using the dimethylmethylene blue (DMMB) assay
[15] with chondroitin 6-sulfate (CS-C: 0–60 μg/ml) as a
standard. The DMMB solution was added to the sample
and standards prior to reading absorbance values at
525 nm in a microplate reader spectrophotometer.
HA assay
Hyaluronic acid was measured using a competitive based
ELISA as previously described [16]. Briefly, samples
or standard HA (HealonW) at various concentrations
(19–10,000 ng/ml) in PBS pH 7.4, were added to 1.5
ml plastic tubes containing biotinylated HABPs (1:200
in 0.05 M Tris–HCl buffer, pH 8.6). The tubes were
incubated at room temperature for 1 hr. and then
samples were added to the microplate, which was pre-
coated with umbilical cord HA (100 μl/well of 10 mg/ml),
and blocked with 1% BSA (150 μl/well). The plate
was then incubated at room temperature for 1 hr.
The wells were subsequently washed and 100 μl of
peroxidase-conjugated anti-biotin antibody (1:2,000 di-
lution in PBS) were added. The plate was incubated
at room temperature for another hour. The reaction
was stopped after 10 minutes with 50 μl/well of 4 M
sulfuric acid and the absorbance was determined using
a microplate reader at 492/690 nm. The concentration
of HA in samples was calculated by reference to a stan-
dard curve.
DNA content
The total amount of DNA was measured by the Hoecht
33258 fluorescent dye assay. A 20 μl aliquot was diluted
in 2 ml of dye/buffer solution and the fluorescence of
the samples was evaluated for excitation at 450 nm and
emission at 555 nm by a spectrophotometer. A standard
curve was prepared from known concentrations of
herring sperm.
RNA extraction and gene expression analysis
Total RNA was isolated from scaffold culture using an
RNA extraction kit (Amershame Bioscience) following
the manufacturer’s protocol and the reagents in all
extraction steps are RNases free solution. Total RNA
(1 μg) was converted to cDNA using a RevertAid™ First
Strand cDNA synthesis kit (MBI Fermentas, Germany).
For determination of gene expression, SYBR Green de-
tection was used and the values were normalized using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Real-time quantitative polymerase chain reaction (PCR)
was performed in a DNA Engine (ABi 7500) using SYBR
GREENER qPCR UNIVERSAL (Invitrogen, USA). Pri-
mer sequences (from Invitrogen) are as follows:
Aggrecan core protein Forward 5’-3’ CTGTTCAGGGA
CAGAATGTGCT; Reverse 5’-3’ TCGATATGCTTCA
CAGTTCTAGGG: Collagen type I Forward 5’-3’ TTTTG
GCCATCTCTTCCTTCA; Reverse 5’-3’ TGTGGATGCC
TCTTGGGTATC: Collagen type II Forward 5’-3’ TCCT
CTTCTTGAGCTGGACTCATTCT; Reverse 5’-3’ CGCT
CTGCAAACTGGAGGTC: SOX9 Forward 5’-3’ GAAGG
TGAAGGTCGGAGTC; Reverse 5’-3’ GAAGATGGTGA
TGGGATTTC. GAPDH Forward 5’-3’ GAAGGTGAAG
GTCGGAGTC; Reverse 5’-3’ GAAGATGGTGATGGG
ATTTC. Relative expression levels for each primer set
were normalized to the expression of GAPDH by the
2-ΔCT method [17].
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Histology
For light microscopy, the samples were fixed in a 0.1 M
phosphate-buffer (pH7.4) solution of 1% (v/v) parafor-
maldehyde and 1.25% (v/v) glutaraldehyde, dehydrated
in alcohol and embedded in polymethylmethacrylate.
Sections (4 μm) were stained with haematoxylin-eosin
(H&E) and Safranin O.
For scanning electron microscopy, the samples were
prefixed for 24 hrs. at 4°C with 2% (v/v) glutaraldehyde
and 2% (v/v) tannic acid in 0.1 M sodium-cacodylate
buffer (pH 7.4). Matrices were dehydrated through a
graded series of ethanol and acetone; critical point dried
using a CPD 7501 critical point Drier, mounted on stubs
and spattered with an ultrathin layer of gold in a SEM
coating system using SPI-MODULE™ Spatter Coater.
Specimens were studied using a JEOL 5910 LV SEM ap-
paratus at an accelerating voltage of 15 kV.
Statistical analysis
Data shown are representative of repeated experiments.
Triplicate samples were used for chemical and biochem-
ical assay. Duplicate samples were used for microscopy
analysis. The data are expressed as mean ± SD. The sig-
nificance of differences between groups was tested using
non-parametric Wilcoxan rank-sum tests. Statistical sig-
nificance was considered as p < 0.05.
Results
Production of glycosaminoglycan molecules
The numbers of non-adhering chondrocytes in the
gelatin were significantly higher than in the collagen
scaffold (5,960 ± 1,113 vs 3,600 ± 285 cells: p < 0.05).
The wet weight of the scaffolds was compared to assess
extracellular matrix production. After 21 days, the gel-
atin scaffold had 1.5 fold increased in wet weight com-
pared to the collagen scaffold (Figure 1A). We next
examined the glycosaminoglycan content produced from
the chondrocytes cultivated in the scaffold (Figure 2).
For each 3 day-time point, the chondrocyte seeded gel-
atin scaffold showed higher levels of s-GAG (p < 0.05 at
day 18 and 21) and HA production (p < 0.05 for all
intervals) released into the media than the chondrocyte
seeded collagen scaffold. After 21 days, the amount of
HA/DNA content in the matrix in the gelatin scaffold
was significantly higher than in the collagen scaffold
(p < 0.05), although the GAG/DNA content in the
matrix of the gelatin scaffold was slightly lower although
not significantly less (p = 0.105) (Figure 1B, C).
The chondrogenic mRNA profile
Chondrogenic gene expression included Aggrecan core
protein, Collagen type I Collagen type II and SOX9 were
measured as shown in Figure 3. The mRNA analysis was
performed at day 7 of the 21 days culture. On day 7,
compared to the collagen scaffold, the expression of
selected genes of the chondrocyte seeded gelatin scaffold
were all significantly lower. After 14 days of cultivation,
Aggrecan core protein and Collagen type II gene expres-
sion were unchanged from day 7, and significantly
decreased at day 21 in both gelatin and collagen scaf-
folds. On day 21, the Aggrecan core protein and
Figure 1 Matrix glycosaminoglycan accumulation in scaffold.
Human articular chondrocytes (5x105 cells) were cultured in each
scaffold for 21 days. The wet weight (A), glycosaminoglycans
content normalized to DNA content: HA (B), s-GAGs (C) were
measured. Asterisk indicates significant (* p < 0.05).
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Collagen type II genes of the chondrocyte seeded gelatin
scaffold had significantly higher expression levels com-
pared to the collagen scaffold (p < 0.05). In contrast to
Aggrecan and Collagen type II gene expression, Collagen
type I gene expression was significantly different between
the chondrocyte seeded gelatin and collagen scaffolds. In
the both scaffold after cultivation for 14 days, Collagen
type I gene expression was not significantly different from
day 7, and was significantly increased at day 21. The
chondrocyte seeded collagen scaffold showed a decrease
of SOX9 gene expression after the 7 day interval while
SOX9 expression of the chondrocytes that were seeded
on the gelatin scaffold was unchanged from day 7, and on
day 21 was decreased in comparison with day 14. Similar
to Aggrecan core protein and Collagen type II, on day 21,
the SOX9 gene expression of chondrocytes seeded on the
gelatin scaffold was significantly higher compared with
chondrocytes seeded on the collagen scaffold.
Scanning electron microscopy
Cell morphology and cell distribution inside the scaffold
was observed after 7 days culture by SEM. Matrix forma-
tion of the chondrocytes on the collagen scaffold was
higher than on the gelatin scaffold, in which space-filled
pores can be observed (Figure 4). Chondrocytes on both
gelatin and collagen scaffolds showed a spherical morph-
ology in agreement with previous studies [18]. The
surfaces of the porous scaffolds are filled with the chon-
drocytes which are embedded in extracellular matrix and
completely filling the pores of the scaffold on day 21. The
surface of the chondrocytes on collagen scaffold was
smoother than the chondrocytes on gelatin scaffold.
Histology
To determine cell penetration and morphology, hematoxy-
lin eosin staining showed an equal distribution of chondro-
cytes in the porous material of both gelatin and collagen
scaffolds (Figure 5A). The sulfated glycosaminoglycan
Figure 2 The accumulative release of glycosaminoglycan:
s-glycosaminoglycan (s-GAG) and hyaluronic acid (HA) from the
gelatin and collagen scaffold into the medium during culture.
Asterisk indicates significant (* p < 0.05) increase of
glycosaminoglycans production at the same time point.
Figure 3 Quantitative RT-PCR analysis of chondrocyte growth on gelatin and collagen scaffold over 21 days cultivation. The results
represent the chondrogenic gene expression (aggrecan core protein, SOX9, collagen type II and collagen type I). Values are expressed as the mean
and standard deviation for 3 independent cultures. Asterisk indicates significant (*p < 0.05) increase of gene expression at the same time point.
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Figure 4 Scanning electron microscope of the surface of gelatin and collagen scaffold. Representative surface images of cell free scaffold, 7
and 21 days after chondrocyte seeding.
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production of the chondrocyte embedded scaffold was
measured by Safranin O staining (Figure 5B). According
to the GAG/DNA in the matrix (Figure 1C), the gelatin
scaffold showed no difference in the intensity of Safranin
O staining as compared to the collagen scaffold.
Discussion
Gelatin, a porous form of denatured collagen, is used as
a potential cell delivery system and to support bovine
chondrocyte metabolism [19]. It has been used as a scaf-
fold for cartilage tissue engineering [20,21]. In addition,
gelatin scaffold (Spongostan™ Johnson & Johnson) has
suitable properties as a 3D chondrocyte matrix for bo-
vine chondrocytes [14]. A collagen scaffold, with its
inherent cartilage biological matrix, has been demon-
strated to be a cell supporter and to enhance chondro-
genic culturing of chondrocytes [12,22-24]. Based on the
fact that the biological composition of gelatin is derived
from collagen, a collagen scaffold should match its
physio-biochemical properties, in vivo biodegradable
property, and on the evidence from chondrocyte culture,
we selected collagen scaffolds for comparison. We evalu-
ated gelatin scaffolds (Spongostan™ Johnson & Johnson)
as chondrocyte 3D cultures for in vitro hyaline cartilage
regeneration using human articular chondrocytes. The
biochemical and histological analyses were designed to
examine the influence of gelatin and collagen scaffolds
on chondrocyte ECM synthesis over a 21-day culture
period. Initially, we counted the numbers of non-adhe-
ring chondrocytes for estimate amount of chondrocytes
which adhered into the scaffold to evaluate adhesive ac-
tivity of chondrocyte to the scaffold and we found the
level of chondrocytes adhering to the gelatin scaffold
was significant less than in the collagen scaffold, due
to the larger pore size (100–300 μm vs 100–200 μm).
Gelatin is derived from denatured collagen, which re-
tains an RGD motif peptide for cell adhesion and pe-
netration. Even during initial cell adhering, there was
evidence that chondrocyte seeded gelatin scaffolds had
higher cell proliferation and chondrocyte matrix pro-
duction, as shown by the DNA content and wet weight
of the chondrocyte seeded gelatin scaffold being signifi-
cantly higher than for the collagen scaffold after 21 days
of culture.
The sulfated glycosaminoglycan production was not
significantly different for both releasing and matrix
forms. This was similar to the results from s-GAG stain-
ing among the two types of scaffold, which had no
significant difference in matrix Safranin O stain inten-
sity. Interestingly, the human chondrocytes seeded on
the gelatin scaffold exhibited the higher HA production,
for both matrix component and released form, than cells
Figure 5 Histological analysis of chondrocyte seeded gelatin and collagen scaffold. (A) Hematoxylin&Eosin and (B) Safranin O stain of
chondrocyte seed gelatin and collagen scaffold after 21 days in cultivation.
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seeded on the collagen scaffold. The HA can serve as
the core molecule for HA binding domains and linking
proteins of cartilage matrix proteoglycans [25]. More-
over, via binding to cell surface receptors, this molecule
plays a role in cell proliferation, morphogenesis and
wound repair [26].
Our study examined quantitative chondrogenic gene
expression at 7 day of a 21 days culture. At 7 days cul-
tivation, the chondrocytes seeded collagen scaffold ex-
pressed higher levels of hyaline cartilage specific genes
(Aggrecan core protein, Collagen type II and SOX9)
than the gelatin scaffold. At day 14, a decrease in tran-
scription factor SOX9 gene expression was observed.
This protein is crucial for induction and regulation of
the chondrocyte phenotype [27]. Aggrecan [28] and
Collagen type II [29] expression are regulated by this
transcription factor. A decrease in SOX9 induction
affects the Aggrecan and Collagen type II expression.
Thus, higher SOX9 expression on day 21 of the chon-
drocytes seeded gelatin scaffold potentially promoted the
higher levels of Aggrecan and Collagen type II gene
expression compared to the chondrocyte seeded collagen
scaffold.
Our study described for the first time the preparation
and characterization of primary human chondrocytes cul-
tured in absorbable haemostatic gelatin (Spongostan™)
scaffold in extracellular matrix production including HA
and GAG and specific chondrocyte differentiation gene
markers. This observation indicated that the gelatin
scaffold retained the chondrogenic response including the
cells had not de-differentiation to the fibroblasts, en-
hanced extracellular matrix (HA and GAG) production
and more potential to stabilized the expressions or mRNA
levels of chondrogenic differentiation gene markers
including SOX9 transcription factor, Aggrecan core pro-
tein and Collagen type II mRNA in late period of cultiva-
tion. Moreover in Collagen type I, dedifferentiation
marker level was lower than chondrocytes cultured in
collagen scaffold suggested that gelatin scaffold reduced
de-differention of the cells. The phenotype maintaining
ability of chondrocytes seeded on a scaffold is important
for repairing cartilage defects. To our knowledge, this is
the first study to report the quantification of HA produc-
tion of a chondrocyte seeded scaffold. The higher HA
production of the chondrocyte seeded gelatin scaffold over
21 days promoted cell proliferation and matrix synthesis
and expression of cartilage specific matrix proteins.
In conclusion, our investigation has shown that a
gelatin scaffold is adequate to support chondrocytes, and
to induce extracellular matrix production of both HA
and s-GAG. The high production of matrix HA from
the chondrocyte seeded gelatin scaffold may prevent
dedifferentiation via transmembrane receptor CD 44,
resulting in promotion of cell proliferation and enhanced
matrix molecule production. In addition, this scaffold
supported expression of many cartilage matrix genes,
including SOX9, Aggrecan and Collagen type II. Since a
gelatin scaffold is a cheaper medical device, and showed
the ability to support chondrocyte expansion and reten-
tion of the chondrogenic phenotype, it should be suit-
able as an alternative for use in in vitro 3D human
chondrocyte culture as a regenerative cartilage model.
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